Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 14/20 | 0.78 |
| ▸ | DRD2 | P14416 | 9/20 | 0.78 |
| ▸ | HTR1A | P08908 | 6/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8431204 | 0.84 | ALDH1A1 (0.64) | HTR2BDRD2HTR1AMEN1GAA | |
| SCHEMBL6649681 | 0.77 | HTR2B (0.73) | HTR2BDRD2HTR1A | |
| SCHEMBL11819664 | 0.77 | DRD4 (0.65) | HTR2BDRD2HTR1AMEN1KMT2A | |
| SCHEMBL7258289 | 0.77 | HTR2B (0.54) | HTR2BDRD2HTR1AMEN1KMT2A | |
| SCHEMBL2983918 | 0.76 | HTR2B (0.70) | HTR2BDRD2HTR1AMEN1KMT2A | |
| SCHEMBL11627660 | 0.76 | ALDH1A1 (0.55) | DRD2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2979920 | 0.75 | HTR2B (0.74) | HTR2BDRD2HTR1AMEN1KMT2A | |
| SCHEMBL4754279 | 0.74 | HTR2B (1.00) | HTR2BDRD2HTR1AMEN1KMT2A | |
| SCHEMBL6525112 | 0.74 | HTR2B (0.73) | HTR2BDRD2HTR1A | |
| SCHEMBL11923385 | 0.74 | SIGMAR1 (0.79) | DRD2KMT2AALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521386-B2 | Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-13 | — | — | US | disclosed |
| US-20220062278-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| WO-2020123670-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062278-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | AR, KLK3, FSHR | HTR2B 2767/4885DRD2 2233/4885HTR1A 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.